Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

Disclosed herein include circuits, compositions, nucleic acids, populations, systems, and methods enabling cells to sense, control, and/or respond to their own population size. In some embodiments, an orthogonal communication channel allows specific communication between engineered cells. Also described herein, in some embodiments, is an evolutionarily robust ‘paradoxical’ regulatory circuit architecture in which orthogonal signals both stimulate and inhibit net cell growth at different signal concentrations. In some embodiments, engineered cells autonomously reach designed densities and/or activate therapeutic or safety programs at specific density thresholds. Methods of treatment are also provided in some embodiments.

Described is a method for identifying pathogenic platelet-activating antibodies in a subject's blood and particularly antibodies implicated in heparin-induced thrombocytopenia (HIT) which comprises the preparation of a platelet releasate from a normal subject's platelets, the combination of the platelet release with a normal subject's platelets, a test subject's blood sample, and analyzing the sample for platelet activation.

Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.

A method for culturing colorectal cancer solid tumor primary cells and colorectal cancer ascites primary tumor cells and supporting reagents. A method for culturing colorectal cancer solid tumor primary cells and colorectal cancer ascites primary tumor cells and supporting reagents. Colorectal cancer solid tumor tissues are treated with mild cell dissociation reagents, and colorectal cancer cells are isolated from ascites with a mild method, thereby ensuring the vitality of cancer cells to the greatest extent. A special serum-free medium is prepared, and colorectal cancer solid tumor-derived tumor cells are cultured in vitro with a suspension culture system to ensure normal expansion of the cancer cells while eliminating the interference of normal cells to the greatest extent. The colorectal cancer primary cell culture obtained by the method are usable for in vitro experiments, second-generation sequencing, building of animal models, and building of cell lines at multiple cell levels.

Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

A method for culturing ginseng cell with high content of ginsenoside, including inducing ginseng cell line: after disinfected and sliced, ultrasonically treating old mountain ginseng, and culturing the old mountain ginseng in a culture medium; screening the ginseng cell line: choosing a variety of culture mediums and using hormones for cell separation and culture, selecting cell lines with better growth morphology and faster growth, and performing solid subculture and liquid suspension culture; optimizing conversion conditions: using acids to treat the chosen cell lines, and controlling the transformation temperature and transformation time, detecting ginsenosides Rg3 and Rh2 in the dried products, determining an optimal transformation condition according to the highest total amount; large-scale industrial production: according to the optimal transformation condition, performing the liquid suspension culture of the selected cell lines and scaling up the scale of culture to obtain large-scale industrial production of ginseng cell products.

The invention provides monocytes expressing CD16 and CD163 and experimental system for drug screening or evaluating drug candidates where the modulation of CD16 and CD163 is desired.

The present invention discloses formulation of a serum-free medium used for human pluripotent stem cells, which comprises the following raw materials: inorganic salt components, organic components, amino acids and amino acid salts, energy substances and metabolic intermediates, vitamins and antioxidants, proteins and polypeptides, trace elements and chromogenic substances; while the culture process comprises the following steps: selecting a basic formulation, performing combination screening, identifying and evaluating results, and testing a new formulation of culture; and proportioning according to the following methods: adding aforesaid raw materials into 950 ml of water for injection, stirring gently until dissolved, and finally adding 2.438 g of sodium bicarbonate, and stirring gently until dissolved, and then adding 1 liter of water for injection, adjusting the pH to the desired value with 1 mol/L sodium hydroxide solution or 1 mol/L hydrochloric acid solution, finally filtering sterilized with 0.1 m diameter filter under positive pressure, and storing the medium solution in dark place at 2 C.-8 C., the invention solves the problem of high cost of domestic import of serum-free formulation.

The invention refers to a method for preparing novel and powerful regulatory B cells (Breg-nov) by contacting cells obtained from the immune system with phosphorothioate oligonucleotide. Methods of suppressing-autoimmunity or suppressing acute or chronic inflammation or repairing a damaged organ or tissue in mammals, including humans, by administering to the mammals in need, Breg-nov cells obtained as herein described.